The Medicare Administrative Contractor with jurisdiction for Biodesix’s De Soto, Kansas laboratory, provides coverage for the Nodify CDT® lung nodule test.
Aim is to develop and commercialize new pipeline oncology biomarker assay in collaboration with Memorial Sloan Kettering Cancer Center and Bio-Rad, Inc.
Scott Hutton, Chief Executive Officer of Biodesix, will present at the 42nd Annual William Blair Growth Stock Conference being held June 6-9 in Chicago
Biodesix today announced that new data were published in the peer-reviewed journal, Diagnostics (Basel), in an article titled, “Analytic and Clinical Validation of a Pan-Cancer NGS Liquid Biopsy Test for the Detection of Copy Number Amplifications, Fusions and Exon Skipping Variants.”
Biodesix announced impactful data on the Primary Immune Response (PIR) test at the IASLC 2022 Targeted Therapies of Lung Cancer Meeting.
Biodesix CEO named in The Healthcare Technology Report’s list of Top 25 Biotech CEOs of 2022, recognizing the most accomplished executives in biotech.
Genomic and proteomic diagnostics for lung cancer help physicians better identify patients eligible for targeted therapy or clinical trial enrollment.
Biodesix, Inc., a data-driven diagnostic solutions company with a focus in lung disease, appoints Dr. Jon Faiz Kayyem to the board of directors.
Spesana and Biodesix Inc. announced today that they have partnered to further streamline and automate the use of molecular diagnostics in clinical workflows across the United States utilizing Spesana’s digital platform solutions for comprehensive lung cancer management.
Biodesix, Inc. announced new interim data published from the large multi-center observational registry study INSIGHT utilizing its novel predictive and prognostic blood-based host immune classifier (the VeriStrat test) to stratify ICI treatment response in patients with advanced NSCLC.